TOKENPOST
1 min read
Add as a preferred source on Google

Sarepta Raises Lower End of 2026 Revenue Guidance

The revision applies to the company's full-year 2026 revenue outlook.

By John Kim
Published
An unmarked medicine vial rests on a raised glass platform. / TokenPost.ai
An unmarked medicine vial rests on a raised glass platform. / TokenPost.ai

Sarepta Therapeutics raised the low end of its 2026 revenue guidance.

The revised outlook covers the full year.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…